Loading
A phase 2/3 trial testing BEBT-209 in triple-negative breast cancer, now recruiting.
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer is a phase 2/3 interventional study registered as NCT07544056, led by BeBetter Med with Hunan Cancer Hospital and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multi-centre, Phase IIb/III Clinical Study to Evaluate BEBT-209 Plus Carboplatin and Gemcitabine Versus Carboplatin Plus Gemcitabine in Locally Advanced or Metastatic Triple-Negative Breast Cancer. Planned enrolment is 446 participants (estimated). The study started in 2026-06-04 and primary completion is expected in 2030-06. No results have been posted on ClinicalTrials.gov.
Shares BEBT-209, BeBetter Med.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).